SKB BIO-B
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 2016-11-22
- Employees
- 1.5K
- Market Cap
- -
- Website
- http://www.kelun-biotech.com
- Introduction
Sichuan Kolumbotai Biopharmaceutical Co., Ltd. (hereinafter referred to as “Colombotai” or the “Company”) is a biomedical company focusing on R&D, manufacturing and commercialization of innovative drugs. Since its establishment in 2016, it has always been committed to solving the medical needs of China and the world at large. With integrated drug development...
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-17
- Target Recruit Count
- 90
- Registration Number
- NCT06726369
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, China
🇨🇳West China Hospital of Sichuan University, Chengdu, China
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 524
- Registration Number
- NCT06279364
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 175
- Registration Number
- NCT05445908
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
A Study of A166 in Patients With Advanced Solid Malignant Tumors
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 120
- Registration Number
- NCT05311397
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 295
- Registration Number
- NCT05294172
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 153
- Registration Number
- NCT03848286
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 109
- Registration Number
- NCT03580564
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China